Quoin Pharmaceuticals, Ltd. (QNRX)
Oxford Ledge is still expanding full research coverage of QNRX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Specialty pharmaceutical company developing QRX003, a topical treatment for rare genetic skin diseases, in late-stage clinical testing.
SEC filings
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-23
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-04
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-07
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- 10-K Annual financial report with audited statements 2026-03-26
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for QNRX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open QNRX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.